Loading
HKSEHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
HK$0.034
HK$0.00 · 0.00%
Kontafarma China Holdings Ltd. directs its business efforts through two principal segments: Pharmaceutical and Fitness. Its Pharmaceutical arm is responsible for the manufacturing and marketing of prescription medications and associated laboratory goods. Meanwhile, the Fitness division oversees the management of health clubs, delivers advisory services for physical well-being and health-related pursuits, and runs a franchise model to generate royalty revenue. Established on March 21, 2011, the company maintains its corporate headquarters in Hong Kong.
Latest quote
HK$0.034
HK$0.00 · 0.00%
Regular session · HKT · Market data may be delayed.
Kontafarma China Holdings Ltd. directs its business efforts through two principal segments: Pharmaceutical and Fitness. Its Pharmaceutical arm is responsible for the manufacturing and marketing of prescription medications and associated laboratory goods. Meanwhile, the Fitness division oversees the management of health clubs, delivers advisory services for physical well-being and health-related pursuits, and runs a franchise model to generate royalty revenue. Established on March 21, 2011, the company maintains its corporate headquarters in Hong Kong.
Day range
Current HK$0.034
52-week range
Current HK$0.034
Regular session · HKT · Market data may be delayed.
Kontafarma China Holdings Ltd. directs its business efforts through two principal segments: Pharmaceutical and Fitness. Its Pharmaceutical arm is responsible for the manufacturing and marketing of prescription medications and associated laboratory goods. Meanwhile, the Fitness division oversees the management of health clubs, delivers advisory services for physical well-being and health-related pursuits, and runs a franchise model to generate royalty revenue. Established on March 21, 2011, the company maintains its corporate headquarters in Hong Kong.
Day range
Current HK$0.034
52-week range
Current HK$0.034
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (HKD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 914.71M HKD | 897.52M HKD | 809.11M HKD | 894.06M HKD | 803.27M HKD |
| Cost of goods sold | 401.07M HKD | 381.36M HKD | 337.82M HKD | 387.84M HKD | 478.2M HKD |
| Gross profit | 513.64M HKD | 516.16M HKD | 471.29M HKD | 506.22M HKD | 396.18M HKD |
| Research and development | 8.37M HKD | 34.63M HKD | 20.75M HKD | 29.11M HKD | 45.63M HKD |
| Selling, general, and administrative | 550.17M HKD | 524.04M HKD | 542.49M HKD | 605.76M HKD | 489.23M HKD |
| Operating expenses | 558.53M HKD | 558.67M HKD | 563.62M HKD | 590.63M HKD | 502.98M HKD |
| Interest income | 1.99M HKD | 5.82M HKD | 3.5M HKD | 5.18M HKD | 3.31M HKD |
| Interest expense | 10.76M HKD | 13.39M HKD | 15.25M HKD | 23.28M HKD | 33.61M HKD |
| Depreciation and amortization | 89.3M HKD | 42.49M HKD | 107.16M HKD | 121.39M HKD | 133.03M HKD |
| Operating income | −242.83M HKD | −42.51M HKD | −164.3M HKD | −137.29M HKD | −97.71M HKD |
| Net income | −427.85M HKD | −75.54M HKD | −28.84M HKD | −41.55M HKD | −15.05M HKD |
Company facts updated Sep 5, 2026.
Cash distributions grouped by calendar year; partial years are marked.
HK$0.004
2013 complete year0.0% since 2012
HK$0.004
2,012
HK$0.004
2,013
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | May 27, 2013 | HK$0.02Annual | May 28, 2013 | Jun 13, 2013 |
Dividend | May 28, 2012 | HK$0.02Annual | May 29, 2012 | Jun 13, 2012 |
Ex-dividend May 27, 2013
HK$0.02
Annual
Record May 28, 2013 · Payment Jun 13, 2013
Ex-dividend May 28, 2012
HK$0.02
Annual
Record May 29, 2012 · Payment Jun 13, 2012
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
